Evaluation of butyrate‐induced production of a mannose‐6‐phosphorylated therapeutic enzyme using parallel bioreactors

Bioreactor process changes can have a profound effect on the yield and quality of biotechnology products. Mannose‐6‐phosphate (M6P) glycan content and the enzymatic catalytic kinetic parameters are critical quality attributes ( CQA s) of many therapeutic enzymes used to treat lysosomal storage diseases ( LSD s). Here, we have evaluated the effect of adding butyrate to bioreactor production cultures of human recombinant β ‐glucuronidase produced from CHO ‐ K 1 cells, with an emphasis on CQA s. The β ‐glucuronidase produced in parallel bioreactors was quantified by capillary electrophoresis, the catalytic kinetic parameters were measured using steady‐state analysis, and mannose‐6‐phosphorylation status was assessed using an M6P‐specific single‐chain antibody fragment. Using this approach, we found that butyrate treatment increased β ‐glucuronidase production up to approximately threefold without significantly affecting the catalytic properties of the enzyme. However, M6P content in β ‐glucuronidase was inversely correlated with the increased enzyme production induced by butyrate treatment. This assessment demonstrated that although butyrate dramatically increased β ‐glucuronidase production in bioreactors, it adversely impacted the mannose‐6‐phosphorylation of this LSD therapeutic enzyme. This strategy may have utility in evaluating manufacturing process changes to improve therapeutic enzyme yields and CQA s.